Takeda expands R&D budget, may look for buyout

Japan's Takeda plans to significantly raise the amount of money it is investing in R&D, according to a report in a Japanese newspaper. The drug developer says it will spend 20 percent of its revenue from drug sales, or about $8.6 billion, on research over the next five years. And it will consider an acquisition to help boost its pipeline. New drug candidates are essential for Takeda, which is facing the loss of patents for drugs that supply 60 percent of its revenue. Takeda recently shuttered development of a new compound to replace Actos for diabetes.

- read the report from MarketWatch on Takeda's plans

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.